[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362770-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362770-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-cd94nkg2a-hla-e-axis-as-a-target-in-cancer-immunotherapy-a-critical-perspective","The CD94/NKG2A-HLA-E Axis as a Target in Cancer Immunotherapy - A Critical Perspective","","Cancer immunotherapy advances following clinical success of PD-1/PD-L1 and CTLA4 checkpoint blockers have intensified the search for additional targets. The CD94/NKG2A inhibitory receptor, expressed on NK-cell and T-cell subsets and interacting specifically with the nonclassic HLA-E molecule, has drawn major attention. This perspective overviews key concepts of the CD94/NKG2A–HLA-E axis biology, including therapeutic blocking strategies, generation of clinical-grade NKG2A monoclonal antibodies, and genetic engineering approaches for adoptive NK-cell therapies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-cd94nkg2a-hla-e-axis-as-a-target-in-cancer-immunotherapy-a-critical-perspective/362770/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-cd94nkg2a-hla-e-axis-as-a-target-in-cancer-immunotherapy-a-critical-perspective/362770.png","ImageObject",300,407,{"name":42,"@type":43},"Sarah ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is the CD94/NKG2A–HLA-E axis considered a relevant target in cancer immunotherapy?","Question",{"text":63,"@type":64},"Because CD94/NKG2A is an inhibitory receptor on NK-cell and T-cell subsets that specifically interacts with the nonclassic HLA-E molecule, making it a biologically actionable checkpoint pathway.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What therapeutic strategies are discussed for the NKG2A pathway?",{"text":68,"@type":64},"Blocking NKG2A–HLA-E interactions and developing NKG2A-specific monoclonal antibodies are discussed, along with engineering approaches to control NKG2A expression to enhance adoptive NK-cell therapies.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges must be addressed when using NKG2A-based adoptive NK-cell approaches?",{"text":72,"@type":64},"Identifying predictive biomarkers of responsiveness, selecting appropriate clinical settings, and optimizing combinatorial treatment regimens are highlighted as major challenges.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362770,1790192752,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","The CD94/NKG2A–HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective  \nMiguel Lpez-Botet1, Carlos Vilches2,3, and Aura Muntasell4,5,6  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Successful clinical development of PD-1/PD-L1 and CTLA4 immune checkpoint blockers intensified the search for other potential targets for cancer immunotherapy. Among them, the CD94/NKG2A inhibitory receptor displayed by NK cell and T-cell subsets, which specifically interacts with the nonclassic HLA-E class I molecule, has attracted special attention. Here, we provide an overview of basic concepts on the CD94/ NKG2A–HLA-E axis biology relevant in the framework of ongoing cancer immunotherapy approaches in different scenarios. First, the effectiveness of blocking the NKG2A–HLA-E\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | interaction in vitro and in preclinical models as well as the presence of infiltrating NKG2A+ CD8+ T cells in some solid tumors has led to the generation of clinical-grade NKG2Aspecific monoclonal antibodies, pioneered by monalizumab, currently tested in clinical trials. Second, controlling NKG2A expression by genetic engineering constitutes a promising approach to improve advanced adoptive NK cell–based immunotherapies. Challenges include identifying predictive biomarkers of responsiveness, selecting appropriate clinical settings, and optimizing combinatorial regimens. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nCancer immunotherapy remains a long-standing ambition which has progressed alongside the knowledge on the immune system and tumor biology, fueled by technological advances. Positive results and disappointments have uncovered the complex challenges faced for promoting an immune response against tumors to effectively improve the clinical outcome, complementing other therapeutic procedures. Among outstanding advances, evidence that antagonizing the function of inhibitory immune receptors (i.e., PD-1/PD-L1 and CTLA4) promotes clinically successful T-cell responses against some tumors boosted the search for other potential target regulatory molecules, generically designated checkpoints.  \nNatural killer (NK) cells are innate immune effectors involved in the response to pathogens, originally identified by their ability to kill tumor cells. Universal accessibility to monoclonal antibody (mAb) production technology and its use as a strategy for the characterization of human leukocyte differentiation antigens, coordinated by international workshops, gradually led to the identification of a variety of surface human NK cell receptors (NKR), revealing the  \n1Department of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain. 2Immunogenetics and Histocompatibility Lab, Instituto de Investigacin Sanitaria Puerta de Hierro- Segovia de Arana, Majadahonda, Spain. 3Organizacin Nacional de Trasplantes, Ministerio de Sanidad, Madri","cbCaicsec3jWU4gQ","https://ap.wps.com/l/cbCaicsec3jWU4gQ","pdf",1208324,"English","# Introduction\n## Checkpoint blockade and target discovery\n## NK cells and inhibitory receptors\n## Key concepts of the CD94/NKG2A–HLA-E axis","[{\"question\":\"Why is the CD94/NKG2A–HLA-E axis considered a relevant target in cancer immunotherapy?\",\"answer\":\"Because CD94/NKG2A is an inhibitory receptor on NK-cell and T-cell subsets that specifically interacts with the nonclassic HLA-E molecule, making it a biologically actionable checkpoint pathway.\"},{\"question\":\"What therapeutic strategies are discussed for the NKG2A pathway?\",\"answer\":\"Blocking NKG2A–HLA-E interactions and developing NKG2A-specific monoclonal antibodies are discussed, along with engineering approaches to control NKG2A expression to enhance adoptive NK-cell therapies.\"},{\"question\":\"What challenges must be addressed when using NKG2A-based adoptive NK-cell approaches?\",\"answer\":\"Identifying predictive biomarkers of responsiveness, selecting appropriate clinical settings, and optimizing combinatorial treatment regimens are highlighted as major challenges.\"}]","The CD94/NKG2A-HLA-E Axis as a Target in Cancer Immunotherapy - A Critical Perspective | PDF",1790149059,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1c324650ee21aab6ad9082fc6bfb773.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa090189e06d266ff8bf3fec686f0d73.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fda983f62af28c06891281de5f97585c.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe83ca52e45bff964f0b98599a0a9c16.webp",980,1311]